Initial Treatment Approach for CLL with Elevated WBC

Key Principles

The American Society of Hematology recommends that treatment should only be started when patients meet specific criteria for active or symptomatic disease, regardless of the absolute lymphocyte count 1, 2
The absolute lymphocyte count should never be used as the sole indicator for treatment in CLL, as symptoms from leukocyte aggregates (leukostasis) rarely occur in CLL patients, unlike in acute leukemias 1, 2, 3

The National Comprehensive Cancer Network recommends treatment should be initiated only when patients demonstrate active disease with at least one of the following criteria: progressive marrow failure, massive or progressive splenomegaly, massive or progressive lymphadenopathy, progressive lymphocytosis, autoimmune cytopenias, or constitutional symptoms 1, 2
The European Society for Medical Oncology suggests that patients with initial lymphocyte counts <30 × 10⁹/L, lymphocyte doubling time should not be used as a single parameter to define treatment indication 1, 2

The American Society of Hematology recommends using Binet staging (Europe) or Rai staging (US) based on physical examination and blood counts to stage the disease 4, 5, 6
The National Comprehensive Cancer Network suggests that early stage disease (Binet A/B without symptoms; Rai 0/I/II without symptoms) should be managed with watch and wait with monitoring every 3 months 4, 5, 6
The European Society for Medical Oncology recommends that advanced stage disease (Binet C; Rai III/IV) or symptomatic disease should be considered for treatment 4, 5, 6

The American Society of Hematology recommends that first-line options include BCL2 inhibitor venetoclax + obinutuzumab, BTK inhibitors (ibrutinib, acalabrutinib) as monotherapy, or venetoclax + ibrutinib combination for patients with del(17p) or TP53 mutation 4, 5, 6, 7
The National Comprehensive Cancer Network suggests that physically fit patients (<65 years, no major comorbidities) should be treated with purine analogs (fludarabine) alone or combined with cyclophosphamide 4, 6, 7
The European Society for Medical Oncology recommends that older patients (>65 years, high comorbidity) should be treated with chlorambucil as a less myelotoxic option 7, 8